Further studies exploring the COX-2 inhibitor rofecoxib and its carborane derivatives as anticancer agents through COX-2-independent inhibition, found these compounds displayed great selectivity in the micromolar range for melanoma and colon cancer cell lines over normal cells, with the mode of action being dependent on cell type [172]. This evidence concerns the gene PTGS2 and malignant colon neoplasm.